CRISPR
CRISPR-based epigenome editing switches genes on by removing methyl tags, without cutting DNA
Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo
Researchers at UNSW Sydney and St. Jude Children’s Research Hospital report a CRISPR-derived “epigenome editing” approach that turns genes on by removing DNA methylation marks rather than cutting DNA. In cell-based experiments, they show that promoter methylation can directly—and reversibly—silence fetal globin genes, a finding they say helps settle a long-running debate about whether methylation is causal or merely correlated with gene shutdown. The work points to a potential path toward safer therapies for sickle cell disease by reactivating fetal hemoglobin without creating DNA breaks.
Nobel Prize-winning scientist Jennifer Doudna has cofounded Aurora Therapeutics, a startup focused on developing personalized gene-editing treatments for rare diseases. The company plans to leverage CRISPR technology and a new FDA regulatory pathway to bring these therapies to market. This initiative builds on recent successes in custom treatments that have saved lives.
Ti AI ṣe iroyin
Health economics specialist Martin Morgenstern stated in an interview that genetic editing will transform medical treatments in the coming decades. According to him, technologies like CRISPR will allow altering specific genes to combat conditions like high cholesterol. This approach promises to be more precise than traditional medications, though it carries inherent risks.
Conservationists are divided over a proposed moratorium on genetic modification of wildlife at an upcoming International Union for Conservation of Nature meeting. While some groups seek a pause to assess risks, others argue that technologies like CRISPR are essential for saving endangered species. The vote could influence funding and policies worldwide.